MabThera Drug Utilisation Study and Patient Alert Card Evaluation in Non-Oncology Patients in Europe: An Infusion Centre-Based Approach
Phase of Trial: Phase IV
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Microscopic polyangiitis; Nephrotic syndrome; Neuromyelitis optica; Pemphigus vulgaris; Primary biliary cirrhosis; Rheumatoid arthritis; Transplant rejection; Wegener's granulomatosis
- Focus Therapeutic Use
- Sponsors Roche
- 12 Apr 2017 Planned End Date changed from 1 Feb 2017 to 31 Aug 2017.
- 12 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 31 Aug 2017.
- 04 May 2016 Planned End Date changed from 1 Oct 2017 to 1 Feb 2017.